TP
GILD icon

Third Point’s Gilead Sciences GILD Stock Holding History

Third Point’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,500,000
Closed -$113M – 54
2013
Q4 		$113M Buy
1,500,000
+1,000,000
+200% +$69.6M 1.94% 24
2013
Q3 		$31.4M Buy
+500,000
New +$29.9M 0.77% 28

Other funds holding GILD

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Third Point's GILD Position: Q1 2014 in Review

Third Point sold out of Gilead Sciences (GILD) in Q1 2014, closing a stake of 1,500,000 shares — an estimated $113M sold.

Third Point first reported a position in GILD in Q3 2013 and held it in 2 quarters. The position peaked at $113M in Q4 2013. 1,188 funds tracked by Wall St. Rank hold GILD as of Q1 2014.

  • Third Point reported no remaining Gilead Sciences position as of Q1 2014 after selling out during the quarter.
  • Third Point sold 1,500,000 Gilead Sciences shares in Q1 2014, an estimated $113M.
  • Third Point first reported a position in Gilead Sciences in Q3 2013 and held it in 2 quarters.
  • Third Point's Gilead Sciences position peaked at $113M in Q4 2013.
  • 1,188 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2014.

Based on Third Point's 13F filing for Q1 2014, filed 15 May 2014.